Merck, Daiichi Sankyo withdraw US BLA for ifinatamab deruxtecan in small cell lung cancer after FDA talks

Merck and Daiichi Sankyo voluntarily withdrew their US Biologics License Application for ifinatamab deruxtecan as a treatment for small cell lung cancer, following discussions with the FDA.

Detected & updated continuously · Source: Nebula